Pulmonary hypertension: Pathophysiology, genetics and functional genomics;Pulmonale hypertonie: Pathophysiologie, genetik und funktionelle genomik

Internist

Volumn 46, Issue 7, 2005, Pages 759-768

  Eickelberg, O ^a   Seeger, W ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Genetics; Pulmonary hypertension; Transforming Growth Factor ; Vascular remodeling

Indexed keywords

BONE MORPHOGENETIC PROTEIN RECEPTOR; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; BOSENTAN; CALCIUM ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; GROWTH FACTOR; ILOPROST; MEMBRANE RECEPTOR; PHOSPHODIESTERASE INHIBITOR; PROSTANOID; SILDENAFIL; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

CELL DIFFERENTIATION; CELL GROWTH; CELL TYPE; COR PULMONALE; FUNCTIONAL GENOMICS; GENE LOCUS; GENE MUTATION; GERM LINE; HUMAN; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; REVIEW;

BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOMICS; HUMANS; HYPERTENSION, PULMONARY; INCIDENCE; POLYMORPHISM, GENETIC; PROTEIN-SERINE-THREONINE KINASES; RISK ASSESSMENT; RISK FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 22144439707     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-005-1431-8     Document Type: Review

References (40)

1. Olschewski H, Rose F, Grunig E et al. (2001) Cellular pathophysiology and therapy of pulmonary hypertension. J Lab Clin Med 138: 367-377
2. Rubin LJ (1997) Primary pulmonary hypertension. N Engl J Med 336: 111-117
3. Gaine SP, Rubin LJ (1998) Primary pulmonary hypertension. Lancet 352: 719-725
4. Olschewski H, Simonneau G, Galie N et al. (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347: 322-329
5. Humbert M, Sitbon O, Simonneau G (2004) Treatment of pulmonary arterial hypertension. N Engl J Med 351: 1425-1436
6. Hoeper MM, Galie N, Simonneau G, Rubin LJ (2002) New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med 165: 1209-1216
7. Ghofrani HA, Wiedemann R, Rose F et al. (2002) Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136: 515-522
8. Simonneau G, Galie N, Rubin LJ et al. (2004) Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43: 5S-12S
9. Durmowicz AG, Stenmark KR (1999) Mechanisms of structural remodeling in chronic pulmonary hypertension. Pediatr Rev 20: e91-e102
10. Hopkins N, McLoughlin P (2002) The structural basis of pulmonary hypertension in chronic lung disease: remodelling, rarefaction or angiogenesis? J Anat 201: 335-348
11. Humbert M, Morrell NW, Archer SL et al. (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43: 13S-24S
12. Pietra GG, Capron F, Stewart S et al. (2004) Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 43: 25S-32S
13. Eickelberg O, Yeager ME, Grimminger F (2003) The tantalizing triplet of pulmonary hypertension-BMP receptors, serotonin receptors, and angiopoietins. Cardiovasc Res 60: 465-467
14. Dresdale DT, Michtom RJ, Schultz M (1954) Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance. Bull N Y Acad Med 30: 195-207
15. Loyd JE, Primm RK, Newman JH (1984) Familial primary pulmonary hypertension: clinical patterns. Am Rev Respir Dis 129: 194-197
16. Morse JH, Jones AC, Barst RJ, Hodge SE, Wilhelmsen KC, Nygaard TG (1997) Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32. Circulation 95: 2603-2606
17. Deng Z, Haghighi F, Helleby L et al. (2000) Fine mapping of PPH1, a gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 2q33. Am J Respir Crit Care Med 161: 1055-1059
18. Nichols WC, Koller DL, Slovis B et al. (1997) Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet 15: 277-280
19. Deng Z, Morse JH, Slager SL et al. (2000) Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67: 737-744
20. Lane KB, Machado RD, Pauciulo MW et al. (2000) Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 26: 81-84
21. Thomson JR, Machado RD, Pauciulo MW P et al. (2000) Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR II, a receptor member of the TGF-beta family. J Med Genet 37: 741-745
22. Newman JH, Trembath RC, Morse JA et al. (2004) Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol 43: 33S-39S
23. Trembath RC (2001) Mutations in the TGF-beta type 1 receptor, ALK1, in combined primary pulmonary hypertension and hereditary haemorrhagic telangiectasia, implies pathway specificity. J Heart Lung Transplant 20: 175
24. Trembath RC, Thomson JR, Machado RD et al. (2001) Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 345: 325-334
25. Harrison RE, Flanagan JA, Sankelo M et al. (2003) Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet 40: 865-871
26. Roberts AB (1998) Molecular and cell biology of TGF-beta. Miner Electrolyte Metab 24: 111-119
27. Massague J, Wotton D (2000) Transcriptional control by the TGF-beta/Smad signaling system. Embo J 19: 1745-1754
28. ten Dijke P, Hill CS (2004) New insights into TGF-beta-Smad signalling. Trends Biochem Sci 29: 265-273
29. Eickelberg O (2001) Endless healing: TGF-beta, SMADs, and fibrosis. FEBS Lett 506: 11-14
30. Chang H, Brown CW, Matzuk MM (2002) Genetic analysis of the mammalian transforming growth factor-beta superfamily. Endocr Rev 23: 787-823
31. Beppu H, Kawabata M, Hamamoto T, Chytil A, Minowa O, Noda T, Miyazono K (2000) BMP type II receptor is required for gastrulation and early development of mouse embryos. Dev Biol 221: 249-258
32. Chang H, Huylebroeck D, Verschueren K, Guo Q, Matzuk MM, Zwijsen A (1999) Smad5 knockout mice die at mid-gestation due to multiple embryonic and extraembryonic defects. Development 126: 1631-1642
33. Chang H, Zwijsen A, Vogel H, Huylebroeck D, Matzuk MM (2000) Smad5 is essential for left-right asymmetry in mice. Dev Biol 219: 71-78
34. Rudarakanchana N, Flanagan JA, Chen H et al. (2002) Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet 11: 1517-1525
35. Nishihara A, WatabeT, Imamura T, Miyazono K (2002) Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension. Mol Biol Cell 13: 3055-3063
36. Atkinson C, Stewart S, Imamura T, Trembath RC, Morrell NW (2001) Immunolocalisation of BMPR-II and TGF-ss type I and II receptors in primary plexogenic pulmonary hypertension. J Heart Lung Transplant 20: 149
37. Morrell NW, Yang X, Upton PD, Jourdan KB, Morgan N, Sheares KK, Trembath RC (2001) Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation 104: 790-795
38. Atkinson C, Stewart S, Upton PD, Machado R, Thomson JR, Trembath RC, Morrell NW (2002) Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 105: 1672-1678
39. Machado RD, Rudarakanchana N, Atkinson C, Flanagan JA, Harrison R, Morrell NW, Trembath RC (2003) Functional interaction between BMPR-II and Tctex-1, a light chain of Dynein, is isoform-specific and disrupted by mutations underlying primary pulmonary hypertension. Hum Mol Genet 12: 3277-3286
40. Foletta VC, Lim MA, Soosairajah J et al. (2003) Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1. J Cell Biol 162: 1089-1098